Post-kala-azar Dermal Leishmaniasis Clinical Trial
Official title:
A Phase II Study to Assess the Safety and Efficacy of the Leishmania Vaccine ChAd63-KH for the Prevention of Post-kala Azar Dermal Leishmaniasis
The actual format of the anticipated LEISH3 trial is under review.
The leishmaniases are poverty-related neglected diseases with a major impact on health worldwide. They affect the poorest of the poor and present a severe barrier to socio-economic development. Caused by infection with one of several species of Leishmania parasite, these diseases occur in 98 countries worldwide and can be broadly classified as tegumentary leishmaniases (TL; affecting the skin and mucosa) and visceral leishmaniasis (VL; affecting internal organs). Worldwide, over 1 million reported cases of TL and 0.5 million reported cases of VL occur each year. Whereas TL are chronic and non-life-threatening, VL is responsible for over 20,000 deaths per year, second only to malaria amongst parasites with regard to mortality. Collectively, approximately 2.4 million disability-adjusted life years are lost to the leishmaniases. No vaccines are currently licensed for any form of human leishmaniasis and the drug arsenal is limited and increasingly compromised by drug resistance. . ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06251739 -
Repurposing Ivermectin for PKDL Treatment
|
Early Phase 1 | |
| Recruiting |
NCT05449717 -
Incidence of Relapse and Post-Kala-Azar Dermal Leishmaniasis in South Sudan
|
||
| Completed |
NCT01975051 -
A Study to Explore Association of Treatment Regimens for Visceral Leishmaniasis, Host Immunological, Genetical and Nutrition Factors With Post-kala-azar Dermal Leishmaniasis (PKDL)
|
Phase 4 | |
| Completed |
NCT03311607 -
Safety and Effectiveness of Short-course AmBisome in the Treatment of PKDL in Bangladesh
|
Phase 4 | |
| Completed |
NCT00486382 -
Open-Label Safety Study of Three-Antigen Leishmania Polyprotein With Adjuvant MPL-SE in Healthy Adults in India
|
Phase 1 |